Huons Global said that the Ministry of Food and Drug Safety has given it the go-ahead to conduct phase 2 clinical trials for Liztox, its botulinum toxin (BTX) product, in treating square jaws.

Through this clinical trial, Huons Global is planning to explore the effective dose of Liztox needed to improve square jaw in adults, while also confirming its effectiveness and safety. As there are no licensed drugs with indications for improving square jaw, the company expects that its treatment will get highly competitive if it receives extended indication for the treatment.

Liztox currently only has indications for improving forehead wrinkles. Still, the company plans to expand indications in the beauty area by also receiving permission for the BTX in treating eye wrinkles by the third quarter of this year.

The company is conducting phase 1 clinical trial for the treatment of stiff muscles of the upper limbs after stroke in Korea and aims to get the ministry’s nod in 2022.

“The Huons Group is making various efforts to extend indications for Liztox, promote overseas clinical and product licenses, expand global GMP-level factories, and develop new products to strengthen the competitiveness of our BTX business,” Huons Global CEO Kim Wan-sup said.

The company will quickly acquire indications in both cosmetic and therapeutic areas to strengthen its presence in the local BTX market, Kim added.